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Abstract
Introduction We analyzed the prevalence of cardiovascular
(CV) disease in patients with rheumatoid arthritis (RA) and its
association with traditional CV risk factors, clinical features of
RA, and the use of disease-modifying antirheumatic drugs
(DMARDs) in a multinational cross-sectional cohort of
nonselected consecutive outpatients with RA (The
Questionnaires in Standard Monitoring of Patients with
Rheumatoid Arthritis Program, or QUEST-RA) who were
receiving regular clinical care.
Methods The study involved a clinical assessment by a
rheumatologist and a self-report questionnaire by patients. The
clinical assessment included a review of clinical features of RA
and exposure to DMARDs over the course of RA. Comorbidities
were recorded; CV morbidity included myocardial infarction,
angina, coronary disease, coronary bypass surgery, and stroke.
Traditional risk factors recorded were hypertension,
hyperlipidemia, diabetes mellitus, smoking, physical inactivity,
and body mass index. Unadjusted and adjusted hazard ratios
(HRs) (95% confidence interval [CI]) for CV morbidity were
calculated using Cox proportional hazard regression models.Page 1 of 10
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BMI = body mass index; CI = confidence interval; CV = cardiovascular; DMARD = disease-modifying antirheumatic drug; HAQ = Health Assessment 
Questionnaire; HR = hazard ratio; MONICA = Multinational Monitoring of Trends and Determinants in Cardiovascular Disease; NSAID = nonsteroidal 
anti-inflammatory drug; QUEST-RA = Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis; RA = rheumatoid arthritis; RF = 
rheumatoid factor; SD = standard deviation; TNF-α = tumor necrosis factor-alpha.
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QUEST-RA project included 4,363 patients from 48 sites in 15
countries; 78% were female, more than 90% were Caucasian,
and the mean age was 57 years. The prevalence for lifetime CV
events in the entire sample was 3.2% for myocardial infarction,
1.9% for stroke, and 9.3% for any CV event. The prevalence for
CV risk factors was 32% for hypertension, 14% for
hyperlipidemia, 8% for diabetes, 43% for ever-smoking, 73% for
physical inactivity, and 18% for obesity. Traditional risk factors
except obesity and physical inactivity were significantly
associated with CV morbidity. There was an association
between any CV event and age and male gender and between
extra-articular disease and myocardial infarction. Prolonged
exposure to methotrexate (HR 0.85; 95% CI 0.81 to 0.89),
leflunomide (HR 0.59; 95% CI 0.43 to 0.79), sulfasalazine (HR
0.92; 95% CI 0.87 to 0.98), glucocorticoids (HR 0.95; 95% CI
0.92 to 0.98), and biologic agents (HR 0.42; 95% CI 0.21 to
0.81; P < 0.05) was associated with a reduction of the risk of
CV morbidity; analyses were adjusted for traditional risk factors
and countries.
Conclusion In conclusion, prolonged use of treatments such as
methotrexate, sulfasalazine, leflunomide, glucocorticoids, and
tumor necrosis factor-alpha blockers appears to be associated
with a reduced risk of CV disease. In addition to traditional risk
factors, extra-articular disease was associated with the
occurrence of myocardial infarction in patients with RA.
Introduction
Rheumatoid arthritis (RA) is associated with increased mortal-
ity, which is predominantly due to accelerated coronary artery
and cerebrovascular atherosclerosis [1], a phenomenon that
occurs in established and early RA [2-5]. Cardiovascular (CV)
events occur approximately a decade earlier in RA than in the
general population [6], suggesting that RA, similarly to diabe-
tes mellitus, is an independent risk factor for premature
ischemic heart disease [7,8].
The use of methotrexate is associated with a significantly
lower risk for CV events in RA patients compared with patients
who had never used disease-modifying antirheumatic drugs
(DMARDs) [9]. Suissa and colleagues [10] found a negative
association between the rate of myocardial infarction and the
current use of any DMARD in a case control study. A study
from Sweden [11] suggested that the risk for developing first
CV events in RA was lower in patients who were treated with
tumor necrosis factor-alpha (TNF-α) blockers. Our objective
was to analyze the prevalence of CV morbidity in a large inter-
national sample of RA patients, its association with traditional
CV risk factors, clinical features of RA, and with the use of
DMARDs.
Materials and methods
QUEST-RA is short for Questionnaires in Standard Monitoring
of Patients with Rheumatoid Arthritis. It is an international
effort to perform an identical cross-sectional review of 100
nonselected consecutive outpatients with RA in three or more
rheumatology clinics in several countries [12]. Countries that
joined QUEST-RA by June 2006 were Denmark, Finland,
France, Germany, Ireland, Italy, the Netherlands, Poland, Ser-
bia, Spain, Sweden, Turkey, the UK, the USA, and Argentina.
Approval for the study was obtained from local internal review
boards or ethics committees, and patients signed an informed
consent form.
Clinical evaluation
Patients were assessed according to a standard protocol to
evaluate rheumatoid arthritis (SPERA) [13]. The rheumatolo-
gists performed a clinical assessment including swollen and
tender joint counts. Information concerning extra-articular fea-
tures and comorbidities, including CV events, was established
by a record review, a detailed clinical examination, and asking
the patient at the time of the visit. The use of all DMARDs,
including dates of start and discontinuation of each DMARD,
was recorded. The most recent rheumatoid factor (RF) values
were collected; RF was considered positive or negative
according to the local reference values any time over the
course of the disease. No training as to how to collect data or
to perform joint counts was provided, and the study was
intended to reflect routine clinical practice. All patients had ful-
filled the American College of Rheumatology 1987 criteria for
the classification of RA during the course of the disease [14].
The presence of subcutaneous nodules, lung disease (nod-
ules, fibrosis, or pleuritis), Felty syndrome, vasculitis, pericardi-
tis, and scleritis was counted for extra-articular disease. CV
events included myocardial infarction, angina, coronary dis-
ease, coronary bypass surgery, and stroke. Dates of these
events were recorded. These data were based on participat-
ing rheumatologists' reports of CV events on their patients and
no other confirmation was required. The presence of hyperlip-
idemia, diabetes mellitus, and hypertension was recorded. No
type specifications for hyperlipidemia or diabetes mellitus
were made.
Patient self-report
The patients completed an expanded self-report health ques-
tionnaire that was first translated to each language; the study
is explained elsewhere in more detail [12]. The questionnaire
included the Health Assessment Questionnaire (HAQ) [15],
years of education, height and weight for body mass index
(BMI), and lifestyle choices such as smoking and frequency of
physical exercise. Smokers were classified as 'nonsmokers'
and 'ever-smokers', including 'current smokers'. Obesity was
defined as BMI of greater than 30. 'Physical inactivity' included
patient responses 'no exercise' or '1 to 2 times a month' versus
exercises 'regular exercise one or more times a week'.Page 2 of 10
(page number not for citation purposes)
Available online http://arthritis-research.com/content/10/2/R30Statistical analyses
Data are presented as means with standard deviations (SDs)
and percentages with 95% confidence intervals (CIs). The
Student t test and chi-square test were used for comparison
between groups.
The prevalence of CV events was calculated including all
patients in the cohort who reported to have had a CV event.
Patients with a CV event before the diagnosis of RA were
excluded from the risk factor analyses. Time-to-event was cal-
culated from the date of diagnosis of RA; patients with no CV
event were censored at the date of evaluation. Univariate Cox
proportional hazard regression models were computed to esti-
mate the risk of any CV event including each of the traditional
CV risk factors and disease characteristics as independent
variables in separate models. Second, multivariate Cox pro-
portional hazard regression models were computed to esti-
mate the risk of all CV events, myocardial infarction, and
stroke. Variables that were included in these models were age,
gender, presence of RF, extra-articular disease, hypertension,
hyperlipidemia, diabetes, smoking, obesity, physical inactivity,
and country. Multivariate analyses were performed including
all patients who had a CV event after a diagnosis of RA and
separately for 'high' and 'low' CV prevalence countries (that is,
countries above and below the median, respectively).
Time of exposure to each DMARD was calculated as the time
(in years) that elapsed between the date of start of a DMARD
and the date of discontinuation, CV event, or date of evalua-
tion, which ever happened first. Each DMARD was analyzed
independently in a Cox regression model, first unadjusted and
then adjusted for age, gender, disease activity/severity (DAS
28 [disease activity score using 28 joint counts] and HAQ),
RA characteristics (RF positivity and presence of extra-articu-
lar manifestations), and the presence of traditional CV risk fac-
tors (hypertension, hyperlipidemia, diabetes, smoking, and
obesity).
Results
Patients
Data collection began in January 2005, and in October 2006
the QUEST-RA project included 4,363 patients at 48 sites in
15 countries. Concerning demographic variables, this cohort
represents a typical RA population: 78% of patients were
female, 90% were Caucasian, the mean (SD) age was 57 (14)
years, the mean disease duration was 11 (9) years, and the
mean duration of education was 10 (4) years. Overall, 74% of
patients had positive RF, ranging from 61% in Germany to
90% in Argentina. Extra-articular disease was present in 24%
of patients, ranging from less than 15% in Italy and the Neth-
erlands to 34% in Denmark (Table 1).
Table 1
Patient characteristics in the QUEST-RA study per country
Country Number of 
sites
Number of 
patients
Age in years 
(mean)
Female (%) Years of 
education (mean)
Disease duration 
in years (mean)
RF-positive (%) Extra-articular 
diseasea (%)
Cardiovascular 
events (all)b (%)
Denmark 3 301 58 76 11 12 74 34 9.97
Finland 3 304 59 72 10 13 75 18 11.18
France 4 389 55 78 11 13 75 21 3.60
Germany 3 225 59 84 10 13 61 36 17.78
Ireland 3 225 57 64 11 11 81 30 6.67
Italy 4 336 61 78 8 10 73 13 8.93
Netherlands 3 317 59 68 11 9 69 13 9.46
Poland 7 642 53 86 12 11 71 33 11.84
Spain 3 301 60 74 10 11 71 23 9.97
Sweden 3 248 59 72 10 12 82 23 8.47
UK 3 126 60 78 12 15 84 30 10.32
Turkey 3 309 52 85 7 11 69 18 6.80
Serbia 1 100 59 88 8 10 71 23 9.00
USA 3 294 57 72 14 9 70 24 11.56
Argentina 2 246 51 90 9 10 90 26 3.66
Total 48 4,363 57 ± 1 78 10 ± 4 11 ± 9 73.7 24.3 9.31
aIncludes nodules, pulmonal fibrosis, pericarditis, vasculitis, Felty syndrome, and scleritis. bMyocardial infarction, angina, coronary heart disease, 
coronary bypass surgery, or stroke. QUEST-RA, Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis; RF, rheumatoid 
factor.Page 3 of 10
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The overall prevalence of CV morbidity (myocardial infarction,
angina, coronary disease, or stroke) was 9.3%, with consider-
able variation between countries (less than 5% in Argentina
and France and greater than 10% in Finland, Germany,
Poland, the UK, and the USA) (Table 1). CV events were more
prevalent in men than in women (Table 2). The overall preva-
lence for the whole cohort of lifetime myocardial infarction was
3.2%, and the prevalence for stroke was 1.9%.
Traditional cardiovascular risk factors
The prevalence of CV risk factors was 33% for hypertension,
14% for hyperlipidemia, 8% for diabetes, 43% for smoking
ever, 72% for physical inactivity, and 18% for obesity. Diabe-
tes was more frequent in men (10%) than in women (7%)
(Table 2). More men than women had ever smoked (68% ver-
sus 37%; P = 0.0001) or were current smokers (26% versus
15%; P = 0.0001).
In a univariate Cox regression analysis, extra-articular disease
was statistically significantly associated with CV morbidity
(Table 3). Among traditional CV risk factors, age, gender,
hypertension, hyperlipidemia, ever-smoking, and diabetes
showed a statistically significant association with CV events.
In a multivariate Cox regression analysis, older age, male gen-
der, hypertension, hyperlipidemia, and ever-smoking were
independently associated with occurrence of CV events
(Table 4). Extra-articular RA (hazard ratio [HR] 2.26; 95% CI
1.29 to 3.97), hyperlipidemia (HR 3.51; 95% CI 1.98 to 6.21),
and ever-smoking (HR 3.20; 95% CI 1.74 to 5.90) were all
associated with myocardial infarction although association of
extra-articular disease was not statistically significant in 'low
prevalence' (of CV disease) countries (Table 4). Hypertension
(HR 2.81; 95% CI 1.49 to 5.30) and diabetes (HR 2.23; 95%
CI 1.12 to 4.44) were associated with stroke; associations
were statistically significant for hypertension in 'high preva-
lence' countries and for diabetes in 'low prevalence' countries
(Table 4).
Disease-modifying antirheumatic drugs and 
glucocorticoids
Patients who had hypertension were treated less frequently
with methotrexate and biologic agents compared with patients
who had no hypertension, but the former were treated more
frequently with leflunomide and glucocorticoids (data not
shown). Table 5 shows the HR for the occurrence of CV
events by year of exposure to each DMARD, when adjusted to
age, gender, disease activity, and traditional risk factors. One
year of methotrexate use was associated with 15%, 18%, and
11% decreases of risk for all CV events, myocardial infarction,
and stroke, respectively. Leflunomide was also associated
with a reduced risk of CV events, and glucocorticoids and sul-
fasalazine were associated with a small but significantly
reduced risk of all CV events. A lower risk for all CV events and
myocardial infarction was also associated with a longer expo-
sition-duration to TNF-α blockers (HR 0.42; 95% CI 0.21 to
0.81; P < 0.05).
Table 2
Cardiovascular morbidity and risk factors in the QUEST-RA study by gender
Male Female
Mean/% 95% CI Mean/% 95% CI
Myocardial infarctiona 8 6–10 2 1–2
Strokeb 3 2–4 2 1–2
Cardiovascular (all)a,c 16 14–18 7 7–8
Age in yearsa 58.9 58.1–59.7 56.3 55.8–56.7
Disease duration in yearsa 8.8 8.2–9.4 10.0 9.7–10.3
Rheumatoid factor-positive 74 71–76 72 70–73
Hypertension 31 28–34 32 31–34
Hyperlipidemia 13 11–16 14 13–15
Diabetes mellitusb 10 8–12 7 6–8
Smoking evera 68 65–71 37 35–38
Smoking nowa 26 23–29 15 14–17
Body mass index ≥30a 13 11–15 19 18–20
Physical inactivityd 68 65–71 73 72–75
aP < 0.001. bP < 0.05. cMyocardial infarct, angina, coronary heart disease, bypass, or stroke. dP < 0.01. CI, confidence interval; QUEST-RA, 
Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis.Page 4 of 10
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This study provides further support to the concept that a pro-
longed use of DMARDs, glucocorticoids, and TNF-α blockers
is associated with a reduced risk of CV events. Furthermore,
extra-articular RA was found to be associated with the occur-
rence of myocardial infarction, and the role of traditional risk
factors for CV morbidity was confirmed.
Incidence and prevalence of cardiovascular disease in 
rheumatoid arthritis
Patients with RA are 30% to 60% more likely to suffer a CV
event compared with the general population [16,17], espe-
cially myocardial infarction [18-20], whereas the incidence
and prevalence of stroke generally have been reported to be
similar in RA as in the general population or in patients with
osteoarthritis [18,20]. Only one study found higher prevalence
of stroke in RA than in controls [16]. We found a lower preva-
lence of stroke compared with other cross-sectional studies
[16,18], although comparative data for the reference from
general populations were not available in our study.
The crude prevalence of CV events differed between coun-
tries (Table 1). Results in the present study, to some extent,
are similar to those in the World Health Organization MONICA
(Multinational Monitoring of Trends and Determinants in Car-
diovascular Disease) project, in which the highest rates of
myocardial infarction were seen in Finland, Poland, and the UK
and lowest in the Mediterranean countries [21], possibly
related to the Mediterranean diet and lifestyle, which are asso-
ciated with a greater than 50% decrease of all-cause and
cause-specific mortality in the general population [22]. How-
ever, our data are not directly comparable to the MONICA
study, in which participants were less than 65 years old,
whereas the QUEST-RA patients are predominantly older
females.
Traditional risk factors for cardiovascular disease
In our study, the frequency of CV events was double in men
compared with women (four times for myocardial infarction)
and does not provide any surprises compared with observa-
tions in the general population [21]. In univariate analyses, all
traditional CV risk factors, except obesity and physical inactiv-
ity, were associated with CV morbidity, and in multivariate
models, hypertension, hyperlipidemia, diabetes, and ever-
smoking remained independent risk factors. Thus, our results
confirm the role of traditional risk factors concerning CV mor-
bidity in patients with RA. However, it needs to be recognized
that our analyses are restricted to people who survived follow-
ing a CV event due to the cross-sectional nature of the study
and some of the predictors being identified may be predictors
of survival following a CV event rather than the occurrence of
the event. Furthermore, we did not collect data on family
history of CV disease, which appears a significant risk factor
for CV morbidity also in patients with RA [23].
Table 3
Univariate analyses for cardiovascular morbidity in patients with rheumatoid arthritis in the QUEST-RA study
Cardiovascular morbidity (percentage of patients)
No Yes Hazard ratio 95% CI P value
Rheumatoid variables
Rheumatoid factor 71.7 77.0 1.02 0.76–1.37 0.881
Extra-articular diseasea 23.0 43.3 1.52 1.19–1.95 0.001
Traditional risk factors
Age in years (mean) 55.8 66.4 1.05 1.04–1.06 0.000
Gender (female) 79.4 64.0 0.42 0.33–0.54 0.000
Hypertension 28.7 62.9 2.97 2.31–3.83 0.000
Hyperlipidemia 11.3 34.0 3.19 2.47–4.13 0.000
Diabetes 6.9 15.8 2.09 1.50–2.92 0.000
Smoking ever 42.6 51.2 1.60 1.25–2.04 0.000
Smoking now 18.3 11.8 0.80 0.55–1.18 0.260
Obesity 17.5 18.3 1.34 0.96–1.86 0.082
Physical inactivity 71.9 73.5 1.00 0.75–1.33 0.993
aIncludes nodules, pulmonal fibrosis, pericarditis, vasculitis, Felty syndrome, and scleritis. CI, confidence interval; QUEST-RA, Questionnaires in 
Standard Monitoring of Patients with Rheumatoid Arthritis.Page 5 of 10
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Multivariate model for cardiovascular morbidity in the QUEST-RA study
Cardiovascular events (all)a hazard ratio (95% CI)
All countries Countries with high prevalence Countries with low prevalence
Age 1.04 (1.03–1.06)b 1.05 (1.03–1.07)b 1.04 (1.01–1.06)c
Gender (female) 0.49 (0.36–0.66)b 0.45 (0.31–0.66)b 0.55 (0.32–0.94)c
Rheumatoid factor 0.95 (0.68–1.33) 0.95 (0.64–1.41) 0.90 (0.46–1.73)
Extra-articular disease 1.33 (1.00–1.78) 1.28 (0.92–1.80) 1.60 (0.91–2.84)
Hypertension 1.95 (1.44–2.63)b 1.85 (1.29–2.64)c 2.23 (1.28–3.90)c
Hyperlipidemia 2.41 (1.78–3.27)b 2.16 (1.50–3.10)b 3.24 (1.86–5.65)b
Diabetes 1.34 (0.92–1.96) 1.05 (0.65–1.69) 2.20 (1.18–4.09)c
Ever-smoking 1.56 (1.16–2.12)c 1.46 (1.01–2.11)d 1.88 (1.10–3.22)c
Obesity 1.16 (0.81–1.66) 1.52 (1.01–2.27)d 0.57 (0.25–1.28)
Physical inactivity 0.93 (0.67–1.30) 1.11 (0.75–1.65) 0.61 (0.33–1.10)
Myocardial infarction hazard ratio (95% CI)
All countries Countries with high prevalence Countries with low prevalence
Age 1.05 (1.02–1.08)c 1.04 (1.01–1.08)c 1.06 (1.00–1.13)c
Gender (female) 0.46 (0.27–0.80)c 0.55 (0.29–1.06) 0.37 (0.13–1.04)
Rheumatoid factor 0.68 (0.36–1.31) 0.68 (0.31–1.48) 0.82 (0.23–2.91)
Extra-articular disease 2.26 (1.29–3.97)c 2.26 (1.17–4.37)c 2.13 (0.71–6.35)
Hypertension 1.45 (0.83–2.53) 1.10 (0.57–2.15) 2.19 (0.72–6.71)
Hyperlipidemia 3.51 (1.98–6.21)b 3.51 (1.80–6.84)b 4.34 (1.41–13.33)c
Diabetes 1.18 (0.59–2.38) 1.27 (0.56–2.90) 1.01 (0.24–4.29)
Ever-smoking 3.20 (1.74–5.90)b 2.47 (1.22–4.99)c 12.14 (2.50–59.05)c
Obesity 0.74 (0.34–1.62) 0.59 (0.22–1.57) 1.36 (0.37–5.01)
Physical inactivity 0.88 (0.46–1.65) 0.96 (0.45–2.07) 0.87 (0.24–3.12)
Stroke hazard ratio (95% CI)
All countries Countries with high prevalence Countries with low prevalence
Age 1.02 (0.99–1.05) 1.03 (1.00–1.06) 0.99 (0.93–1.05)
Gender (female) 0.59 (0.31–1.12) 0.66 (0.31–1.42) 0.37 (0.10–1.39)
Rheumatoid factor 0.95 (0.45–2.00) 0.88 (0.38–2.06) 2.67 (0.40–17.71)
Extra-articular disease 1.41 (0.77–2.58) 1.43 (0.69–2.94) 1.31 (0.40–4.30)
Hypertension 2.81 (1.49–5.30)c 2.95 (1.43–6.11)c 2.37 (0.61–9.20)
Hyperlipidemia 1.18 (0.60–2.31) 0.69 (0.27–1.76) 3.69 (1.16–11.78)c
Diabetes 2.23 (1.12–4.44)d 1.70 (0.71–4.07) 4.63 (1.31–16.40)c
Ever-smoking 1.66 (0.89–3.09) 1.74 (0.82–3.69) 1.31 (0.37–4.63)
Obesity 0.72 (0.31–1.68) 0.77 (0.28–2.08) 0.56 (0.11–2.69)
Physical inactivity 1.01 (0.50–2.03) 1.30 (0.59–2.87) 0.52 (0.13–2.09)
High and low values of each cardiovascular event are based on the median. All variables are included simultaneously in the model, adjusted for 
country. aMyocardial infarct, angina, coronary heart disease, bypass, or stroke. bP < 0.001. cP < 0.01. dP < 0.05. CI, confidence interval; QUEST-
RA, Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis.Page 6 of 10
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frequent consequence of arthritis. In the general population,
the frequency of weekly physical activity of three or more times
is associated with reduced CV morbidity [24]. In the present
study, only 13% of patients exercised three or more times a
week [25]. Physical inactivity (exercise frequency '1 to 2 times
a month' and 'none') was not associated with CV disease in
our analyses.
Cardiovascular morbidity and rheumatoid arthritis-
related risk factors
RA is associated with premature and accelerated atheroscle-
rosis [16,26]. Carotid artery ultrasound and coronary angiog-
raphy have shown that atheromatosis is more frequent in RA
than controls [27,28] and is related to the extent of radio-
graphic damage of joints, which, in turn, is indicative of sus-
tained inflammation [29]. Moreover, multivessel coronary
artery calcifications in RA are related to smoking and an
elevated sedimentation rate [4]. An elevated C-reactive pro-
tein at baseline predicted CV mortality over the follow-up of 10
years in patients with inflammatory polyarthritis in general and
particularly in RF-positive patients [30,31]. Some processes
intrinsic to the pathogenesis of RA play important roles in CV
damage and its clinical consequences: abnormal endothelial
function [32], autoantibodies against oxidized low-density lipo-
protein [33], and levels of serum mannose-binding leptin [34].
Van Halm and colleagues [9] found an association between
CV disease and seropositive and erosive RA, and Turesson
and colleagues [8,35] between CV morbidity and mortality
and extra-articular disease. The present study lends further
support to the significant association between extra-articular
disease and CV morbidity, and this observation underlines
higher CV morbidity in severe RA.
Antirheumatic drugs and cardiovascular disease
Some of the medications used to treat RA might increase the
risk for CV morbidity. The risk of myocardial infarction is
increased in nonsteroidal anti-inflammatory drug (NSAID) and
cyclooxygenase 2 inhibitor users, especially with rofecoxib
[36,37].
Glucocorticoids might increase CV morbidity by promoting
proatherosclerotic lipid profiles [38,39]. Two recent articles
show an increased rate of CV events with long-term use of glu-
cocorticoids [10,40]. However, Davis and colleagues [41]
found no association between cumulative glucocorticoid
exposure and CV events in RA patients followed for a median
of 15 years, after adjusting for other CV risk factors and mark-
ers of RA activity. In the present study, long-term use of gluco-
corticoids was independently associated with a reduced risk
of 'all' CV events (Table 5).
The use of methotrexate has been associated with a signifi-
cantly lower risk for CV events in RA patients compared with
patients who had never used DMARDs [9]. Long-term follow-
up of RA patients has shown that the use of methotrexate is
significantly associated with reduced overall and CV mortality
[42].
Suissa and colleagues [10], in a case control study, found that
the use of DMARDs was associated with a decreased rate of
myocardial infarction. However, Solomon and colleagues [40],
in a case control study, found a higher risk for CV events in
patients who had received cyclosporine, azathioprine, or leflu-
nomide. In our study, longer use of DMARDs such as meth-
otrexate, leflunomide, and sulfasalazine was associated with a
decreased risk of CV disease. The association remained sta-
tistically significant for myocardial infarction with methotrexate
(P < 0.001) and sulfasalazine (P < 0.05), even when adjusted
Table 5
Years of exposure to disease-modifying antirheumatic drugs and cardiovascular morbidity in patients with rheumatoid arthritis in 
the QUEST-RA study
HRa (95% CI) CV all types HRb (95% CI) CV all types HRc (95% CI)
CV all types Myocardial infarction Stroke
Methotrexate 0.82 (0.79–0.86)d 0.84 (0.80–0.87)d 0.85 (0.81–0.89)d 0.82 (0.74–0.91)d 0.89 (0.82–0.98)e
Glucocorticoids 0.94 (0.92–0.97)d 0.95 (0.93–0.97)d 0.95 (0.92–0.98)d 0.96 (0.91–1.00) 0.98 (0.93–1.03)
Antimalarials 0.94 (0.91–0.98)f 0.95 (0.91–0.99)f 0.98 (0.94–1.02) 0.94 (0.85–1.03) 0.87 (0.76–1.01)
Sulfasalazine 0.91 (0.87–0.96)d 0.92 (0.88–0.97)f 0.92 (0.87–0.98)f 0.82 (0.69–0.98)e 0.90 (0.79–1.03)
Gold 0.96 (0.92–1.00)e 0.96 (0.92–1.00)e 0.99 (0.95–1.03) 1.04 (0.98–1.10) 0.98 (0.89–1.07)
Leflunomide 0.52 (0.38–0.72)d 0.55 (0.41–0.75)d 0.59 (0.43–0.79)f 0.52 (0.26–1.06) 0.91 (0.65–1.28)
TNF-α blockers 0.67 (0.53–0.85)f 0.71 (0.56–0.89)f 0.64 (0.49–0.83)f 0.42 (0.21–0.81)e 0.64 (0.39–1.05)
aCrude hazard ratio. bAdjusted hazard ratio by age and gender. cAdjusted hazard ratio by age, gender, disease activity/severity (DAS 28 [disease 
activity score using 28 joint counts] and Health Assessment Questionnaire), rheumatoid arthritis characteristics (rheumatoid factor-positive and 
extra-articular manifestations), and traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking ever, and obesity). dP < 
0.001. eP < 0.05. fP < 0.01. CI, confidence interval; CV, cardiovascular; QUEST-RA, Questionnaires in Standard Monitoring of Patients with 
Rheumatoid Arthritis; TNF-α, tumor necrosis factor-alpha.Page 7 of 10
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ing, which is a risk factor for both CV disease and RA [43]. In
contrast, the use of antimalarials and intramuscular gold was
not associated with a change of the risk of CV disease. In one
report, atherogenic lipid profiles of RA patients improved after
specific therapy for arthritis, primarily due to the increase of
serum high-density lipoprotein cholesterol levels [44].
With respect to TNF-α blockers, infliximab may improve
endothelial function in RA after 12 weeks of therapy [45], sug-
gesting that inflammation is a mediator of endothelial dysfunc-
tion, although such beneficial effects do not appear to sustain
for a long time [46,47]. A recent study suggested that the risk
for developing first CV events in RA is lower in patients treated
with TNF-α blockers [11]. However, that study did not control
for most of the traditional risk factors for accelerated athero-
sclerosis. On the other hand, two case control studies showed
no reduction of infarction rate in RA with TNF-α blockers
[10,41]. Other recent reports from large databases show dis-
cordant results on CV disease incidence in TNF users versus
nonusers [48-50]. In the present study, longer use of TNF-α
blockers was associated with a reduced risk of CV disease
although limited availability of biologics might interfere with the
results. Furthermore, patients with suspected CV disease may
not be prescribed biologic agents.
Several limitations are to be recognized. First, QUEST-RA is a
cross-sectional study with a possible left censorship concern-
ing CV events. Many patients may have experienced a fatal CV
event and, therefore, could not be included in this study. Sec-
ond, all data are based on participating rheumatologists'
reports and no verification of data was performed. Therefore,
it is possible that some data could be missed. Third, data on
the longitudinal use of NSAIDs or cyclooxygenase 2 inhibitors
were not collected. Fourth, the extent of radiographic erosions
(representing cumulative disease activity) was not analyzed in
the present study. Despite limitations, QUEST-RA is a unique
program that has succeeded to date in collecting data on
clinical RA patients according to an identical protocol in vari-
ous locales in various countries and various cultures and pro-
vides data that are not available from any other resources at
this time.
Conclusion
Our study provides further support of the influence of both tra-
ditional and RA-specific risk factors in the development of CV
events, especially myocardial infarction. As assessed by this
study, the risk was lower with the prolonged use of
methotrexate, sulfasalazine, glucocorticoids, leflunomide, and
TNF-α blockers.
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